| Literature DB >> 34994074 |
Yilan Ge1, Lihua Zhang1, Yan Gao1, Bin Wang1, Xin Zheng1.
Abstract
AIMS: This study explored the association between socio-economic status (SES) and mortality among patients hospitalized for heart failure (HF) in China. METHODS ANDEntities:
Keywords: Heart failure; Mortality; Socio-economic status
Mesh:
Year: 2022 PMID: 34994074 PMCID: PMC8934978 DOI: 10.1002/ehf2.13762
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Baseline characteristics stratified by the number of socio‐economic risk factors
| Total | Number of SERFs | ||||||
|---|---|---|---|---|---|---|---|
| 0 ( | 1 ( | 2 ( | 3 ( | 4 ( |
| ||
|
| |||||||
| Age, years (IQR) | 67 (57, 75) | 48 (41, 54) | 66 (58, 74) | 67 (59, 75) | 69 (63, 77) | 77 (69, 81) | <0.001 |
| Female, | 1306 (36.6) | 50 (13.9) | 240 (22.1) | 400 (38.6) | 453 (53.3) | 163 (69.7) | <0.001 |
|
| |||||||
| LVEF, % (IQR) | 43 (33, 56) | 35 (27, 45) | 42 (33, 56) | 44 (33, 56) | 46 (36, 58) | 47 (38, 57) | <0.001 |
| NYHA, | <0.001 | ||||||
| NYHA II | 450 (12.6) | 51 (14.2) | 180 (16.5) | 124 (12.0) | 73 (8.6) | 22 (9.4) | |
| NYHA III | 1573 (44.1) | 163 (45.4) | 488 (44.9) | 478 (46.1) | 363 (42.7) | 81 (34.6) | |
| NYHA IV | 1535 (43.0) | 143 (39.8) | 418 (38.4) | 432 (41.7) | 411 (48.4) | 131 (56.0) | |
| Unknown | 9 (0.3) | 2 (0.6) | 2 (0.2) | 2 (0.2) | 3 (0.4) | 0 (0) | |
| HR, b.p.m. (IQR) | 85 (72, 100) | 89 (77, 102) | 82 (70, 98) | 84 (72, 100) | 87 (75, 101) | 86 (75, 98) | <0.001 |
| SBP, mmHg (IQR) | 130 (115, 148) | 126 (111, 144) | 130 (115, 147) | 130 (115, 147) | 130 (117, 150) | 134 (120, 153) | <0.001 |
| Albumin, g/L (IQR) | 38.9 (35.9, 41.9) | 39.4 (35.9, 42.6) | 39.1 (35.9, 42.3) | 38.7 (36.0, 41.5) | 38.6 (35.6, 41.4) | 38.4 (35.6, 41.9) | 0.02 |
| hs‐cTnT, ng/L (IQR) | 21.0 (12.7, 39.6) | 19.6 (11.9, 37.0) | 20.6 (12.3, 38.3) | 21.5 (13.2, 42.1) | 21.3 (12.9, 39.4) | 22.6 (13.7, 43.3) | 0.09 |
| NT‐proBNP, pg/mL (IQR) | 1486 (613, 3248) | 976 (476, 2141) | 1281 (510, 2820) | 1661 (688, 3419) | 1821 (752, 3645) | 1818 (775, 3600) | <0.001 |
| Na, mmol/L (IQR) | 140 (137, 142) | 141 (138, 143) | 140 (137, 142) | 140 (137, 142) | 140 (137, 142) | 140 (137, 143) | 0.02 |
| eGFR, mL/min/1.73 m2 (IQR) | 68.6 (53.4, 84.4) | 84.1 (69.3, 96.2) | 67.3 (52.9, 84.0) | 69.2 (52.5, 83.0) | 65.9 (52.7, 80.5) | 63.2 (48.5, 75.5) | <0.001 |
| Current smoking, | 908 (25.5) | 179 (49.9) | 279 (25.6) | 242 (23.4) | 168 (19.8) | 40 (17.1) | <0.001 |
|
| |||||||
| Hypertension | 2049 (57.4) | 181 (50.4) | 677 (62.2) | 586 (56.6) | 474 (55.8) | 131 (56.0) | <0.001 |
| Coronary heart disease | 2062 (57.8) | 129 (35.9) | 668 (61.4) | 594 (57.3) | 513 (60.4) | 158 (67.5) | <0.001 |
| Prior revascularization | 557 (15.6) | 41 (11.4) | 250 (23.0) | 153 (14.8) | 92 (10.8) | 21 (9.0) | <0.001 |
| Atrial fibrillation | 1300 (36.4) | 85 (23.7) | 395 (36.3) | 369 (35.6) | 364 (42.8) | 87 (37.2) | <0.001 |
| Valvular heart disease | 584 (16.4) | 52 (14.5) | 164 (15.1) | 177 (17.1) | 153 (18.0) | 38 (16.2) | 0.37 |
| Diabetes mellitus | 1110 (31.1) | 111 (30.9) | 407 (37.4) | 307 (29.6) | 226 (26.6) | 59 (25.2) | <0.001 |
| Stroke | 725 (20.3) | 23 (6.4) | 267 (24.5) | 210 (20.3) | 166 (19.5) | 59 (25.2) | <0.001 |
| COPD | 674 (18.9) | 29 (8.1) | 198 (18.2) | 207 (20.0) | 182 (21.4) | 58 (24.8) | <0.001 |
| Anaemia | 825 (23.1) | 38 (10.6) | 261 (24.0) | 261 (25.2) | 215 (25.3) | 50 (21.4) | <0.001 |
|
| |||||||
| ACEI/ARB | 1849 (51.8) | 236 (65.7) | 574 (52.8) | 517 (49.9) | 412 (48.5) | 110 (47.0) | <0.001 |
| Beta‐blocker | 2111 (59.2) | 275 (76.6) | 675 (62.0) | 605 (58.4) | 437 (51.4) | 119 (50.9) | <0.001 |
| MRA | 2263 (63.4) | 260 (72.4) | 688 (63.2) | 647 (62.5) | 522 (61.4) | 146 (62.4) | 0.006 |
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HR, heart rate; hs‐cTnT, high sensitivity cardiac troponin T; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal brain natriuretic peptide precursor; NYHA, New York Heart Association; SBP, systolic blood pressure; SERFs, socio‐economic risk factors.
Figure 1Kaplan–Meier survival curves for 1 year all‐cause mortality by socio‐economic status indicators in patients hospitalized for heart failure. (A) One year all‐cause mortality by income level; (B) 1 year all‐cause mortality by employment status; (C) 1 year all‐cause mortality by educational attainment; (D) 1 year all‐cause mortality by partner status.
Figure 2Kaplan–Meier survival curves for 1 year all‐cause mortality by the number of socio‐economic risk factors (SERFs) in patients hospitalized for heart failure.
Hazard ratios for 1 year mortality according to socio‐economic status indicators
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| ||||||||
|
| |||||||||||||||||
| High level | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | |||||||
| Middle level | 1.35 | 1.03–1.76 | 0.03 | 1.33 | 1.02–1.75 | 0.04 | 1.40 | 1.06–1.83 | 0.02 | 1.39 | 1.06–1.83 | 0.02 | 1.32 | 1.00–1.74 | 0.05 | ||
| Low level | 1.75 | 1.33–2.29 | <0.01 | 1.74 | 1.32–2.28 | <0.01 | 1.84 | 1.40–2.42 | <0.01 | 1.82 | 1.38–2.39 | <0.01 | 1.61 | 1.21–2.14 | <0.01 | ||
| Unknown | 1.44 | 1.08–1.90 | 0.01 | 1.39 | 1.04–1.84 | 0.02 | 1.53 | 1.15–2.02 | <0.01 | 1.50 | 1.13–1.99 | <0.01 | 1.39 | 1.04–1.86 | <0.01 | ||
|
| |||||||||||||||||
| Employed | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | |||||||
| Unemployed | 2.17 | 1.71–2.74 | <0.01 | 1.86 | 1.43–2.41 | <0.01 | 1.53 | 1.18–1.98 | <0.01 | 1.50 | 1.16–1.95 | <0.01 | 1.43 | 1.10–1.86 | <0.01 | ||
|
| |||||||||||||||||
| High level | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | |||||||
| Middle level | 1.20 | 0.99–1.47 | 0.07 | 1.21 | 0.99–1.47 | 0.07 | 1.16 | 0.95–1.42 | 0.15 | 1.16 | 0.94–1.41 | 0.16 | 1.05 | 0.86–1.30 | 0.62 | ||
| Low level | 1.53 | 1.28–1.83 | <0.01 | 1.43 | 1.19–1.73 | <0.01 | 1.45 | 1.20–1.76 | <0.01 | 1.42 | 1.17–1.72 | <0.01 | 1.25 | 1.03–1.53 | 0.03 | ||
|
| |||||||||||||||||
| Having a partner | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | |||||||
| Unpartnered status | 1.35 | 1.14–1.59 | <0.01 | 1.25 | 1.05–1.48 | 0.01 | 1.25 | 1.05–1.48 | 0.01 | 1.24 | 1.04–1.47 | 0.02 | 1.22 | 1.03–1.46 | 0.02 | ||
CI, confidence interval; HR, hazard ratio.
Model 1, unadjusted; Model 2, adjusted for demographic characteristics; Model 3, Model 2 plus adjustment for clinical characteristics and comorbidities; Model 4, Model 3 plus adjustment for treatments; Model 5, Model 4 plus mutual adjustment for socio‐economic status indicators.
Hazard ratios for 1 year all‐cause mortality of heart failure patients according to the number of coexisting socio‐economic risk factors
| Number of coexistent SERF | Model 1 | Model 2 | Model 3 | Model 4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |||||
| 0 | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | 1.00 | (Reference) | ||||
| 1 | 2.01 | 1.33–3.03 | <0.01 | 1.69 | 1.10–2.60 | 0.02 | 1.56 | 1.01–2.39 | 0.04 | 1.52 | 0.99–2.33 | 0.06 |
| 2 | 2.72 | 1.81–4.09 | <0.01 | 2.38 | 1.55–3.65 | <0.01 | 2.11 | 1.37–3.23 | <0.01 | 2.01 | 1.31–3.09 | <0.01 |
| 3 | 3.27 | 2.17–4.94 | <0.01 | 2.87 | 1.84–4.46 | <0.01 | 2.61 | 1.68–4.05 | <0.01 | 2.45 | 1.57–3.83 | <0.01 |
| 4 | 3.89 | 2.43–6.22 | <0.01 | 3.36 | 2.02–5.61 | <0.01 | 3.34 | 2.00–5.58 | <0.01 | 3.20 | 1.91–5.35 | <0.01 |
|
| <0.01 | <0.01 | <0.01 | <0.01 | ||||||||
CI, confidence interval; HR, hazard ratio; SERF, socio‐economic risk factor.
Model 1, unadjusted; Model 2, adjusted for demographic characteristics; Model 3, Model 2 plus adjustment for clinical characteristics and comorbidities; Model 4, Model 3 plus adjustment for treatments.
Improvement of predictive performance by adding the socio‐economic risk factor score
| Harrell | NRI analysis | IDI analysis | ||||
|---|---|---|---|---|---|---|
|
|
| Change in NRI% (95% CI) |
| Change in IDI% (95% CI) |
| |
| Model 1 | 0.727 | Reference | Reference | Reference | Reference | Reference |
| Model 2 | 0.738 | 0.002 | 15.5 (6.8, 24.2) | <0.001 | 0.7 (0.4, 1.1) | <0.001 |
CI, confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification improvement.
Model 1: adjusted for demographic characteristics, clinical characteristics, comorbidities, and treatments (including age, sex, systolic blood pressure at admission, heart rate at admission, New York Heart Association class, left ventricular ejection fraction, serum sodium, serum albumin, high sensitivity cardiac troponin T, N‐terminal brain natriuretic peptide precursor, estimated glomerular filtration rate, current smoking, coronary heart disease, chronic obstructive pulmonary disease, anaemia, valvular heart disease, diabetes mellitus, atrial fibrillation, and prescription of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, beta‐blocker, and mineralocorticoid receptor antagonist); Model 2: Model 1 plus the socio‐economic risk factor score.